About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

NCT02013180·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Bagcilar Training and Research Hospital

Age

Any age

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

Patients with LUTS and elevated serum PSA levels and/or suspicious rectal examination

You may not be if

usage of zinc included drugs, older prostatic operations, older prostatic radiotherapy, older prostatic biopsies, chronic rectal diseases (anal fissure, hemorrhoid, etc..), PIN(prostatic intraepithelial neoplasia) and ASAP(atypical small acinar proliferation) in pathologic evaluation.

The record

StatusCompleted

PhaseNo phase

Taking part480

StartedJul 2012

UpdatedApr 16, 2019

Conditions

Prostate Cancer Detection

Where1

Bagcilar Training and Research Hospital-Depertmant of Urology
Istanbul, Bagcilar, Turkey (Türkiye)